ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
US Judge Dismisses Gautam Adani Criminal Charges 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
